FMP
NASDAQ
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
42.25 USD
-1.26 (-2.98%)
Valuation Date:
Apr 18, 2024 4:00 PM
Share Price on Valuation Date
$42.25
Stock Beta
1.193
Shares Outstanding
62446004